Clinical Trial

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Study acronym: PEACE-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-01-25; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2021-07-21
Trial Details
NCT Number NCT03819101
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: National Cancer Institute, France
Conditions Prostate Cancer
Enrollment 1,210 participants
Start Date 2019-06-06
Primary Completion 2042-03 (estimated)
Study Completion 2042-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-06